Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 47

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 47
---
 the next chapter of our Play to Win Strategy and: • increased investments in our pipeline to fully realize long-term growth potential, bolstered by successful launches and R&D progress; • launched strategic cost initiatives, with most of the savings to be reallocated to fund innovation and growth drivers; • announced our intention to separate the Consumer Healthcare Business ; and • reiterated our capital allocation policy. 1) Focus on growth • Dupixent (dupilumab) (1) – By leveraging the product’s unique mechanism of action targeting the type 2 inflammation pathway and its favorable safety profile, we have raised our ambition for peak sales of Dupixent. In September 2024, Dupixent was approved in the US by the FDA as the first-ever biologic medicine for patients with Chronic Obstructive Pulmonary Disease (COPD). • Vaccines – Sanofi has progressed to continued strong growth, driven by four core franchises: Influenza; Meningitis; Polio, Pertussis a Hib (PPH) & Boosters; and Respiratory syncytial virus (RSV). • Pipeline – We are focusing our investments on projects in immunology, rare diseases, neurology and vaccines. 2) Lead with innovation We have been able to shift from a priority medicine list to a steady flow of medicines in a refocused, consistent pipeline. Our pipeline is showing potential opportunities for market-leading products. To continue fueling our promising pipeline and enhance our position in our core therapeutic areas, we have: i. acquired Inhibrx, Inc,. adding a potential best-in-class rare disease medicine for Alpha-1 Antitrypsin Deficiency to the pipeline; ii. entered into a strategic collaboration with Synthekine to develop and commercialize IL-10 receptor agonists for the treatment of inflammatory diseases; iii. established a strategic collaboration with Belharra to advance the discovery of novel small molecule therapeutics for immunological diseases; iv. established a co-exclusive licensing agreement with Novavax to co-commercialize a COVID-19 vaccine and develop novel flu- COVID-19 combination vaccines; v. entered into an exclusive worldwide out-licensing agreement with Vir Biotechnology for three clinical-stage masked T-cell engagers and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases, medicines previously acquired by Sanofi from Amunix Pharmaceuticals; vi. entered into a three-way collaboration with Formation Bio and OpenAI to build AI-powered software to accelerate drug development and bring new medicines to